Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
Real-time Estimate Cboe BZX  -  05/23 02:43:05 pm EDT
10.53 USD   +5.04%
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1 2422 006707438--
Enterprise Value (EV)1 1 2421 891526241293321
P/E ratio -13,6x-16,7x-12,7x-4,96x-6,06x-17,0x
Yield ------
Capitalization / Revenue -96,7x20,3x6,91x4,31x2,62x
EV / Revenue -91,1x15,1x3,80x2,88x1,92x
EV / EBITDA -15,0x-15,8x-4,59x-1,93x-2,81x-2,88x
Price to Book 6,24x18,8x3,89x4,16x3,27x2,65x
Nbr of stocks (in thousands) 39 72840 51443 64443 718--
Reference price (USD) 31,349,516,210,010,010,0
Announcement Date 03/12/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 -20,834,963,4102167
EBITDA1 -82,8-120-115-125-104-111
Operating profit (EBIT)1 -83,0-120-115-105-92,6-52,2
Operating Margin --578%-331%-166%-91,0%-31,2%
Pre-Tax Profit (EBT)1 -81,0-119-55,3-76,5-110-89,6
Net income1 -81,0-119-55,3-89,4-83,1-43,3
Net margin --575%-158%-141%-81,7%-25,8%
EPS2 -2,30-2,97-1,28-2,02-1,65-0,59
Dividend per Share2 ------
Announcement Date 03/12/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 8,979,6010,511,412,330,9
EBITDA1 -28,6-35,5--30,0-32,0-33,0
Operating profit (EBIT)1 -28,7-35,8-27,7-29,0-30,1-13,1
Operating Margin -320%-373%-264%-254%-246%-42,5%
Pre-Tax Profit (EBT)1 -28,9-36,9-28,1-28,5-29,69,47
Net income1 -28,9-36,9-28,1-28,9-30,0-2,58
Net margin -322%-384%-268%-253%-245%-8,35%
EPS2 -0,66-0,85-0,64-0,66-0,68-0,05
Dividend per Share ------
Announcement Date 11/04/202102/24/202205/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -115182197145117
Leverage (Debt / EBITDA) -0,96x1,58x1,59x1,39x1,05x
Free Cash Flow1 -75,5-91,4-103-63,0-115-112
ROE (Net Profit / Equities) -47,7%-78,3%-38,7%-44,7%-64,2%-50,4%
Shareholders' equity1 17015214320012985,9
ROA (Net Profit / Asset) -44,0%-68,5%-32,1%-32,7%-68,6%-51,0%
Assets1 18417417227312184,9
Book Value Per Share2 5,012,644,172,413,063,79
Cash Flow per Share2 -2,09-2,27-2,37-2,09-0,96-
Capex1 1,970,180,67---
Capex / Sales -0,84%1,91%---
Announcement Date 03/12/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 438 056 013
Net sales (USD) 34 897 000
Number of employees 148
Sales / Employee (USD) 235 791
Free-Float 87,7%
Free-Float capitalization (USD) 384 003 093
Avg. Exchange 20 sessions (USD) 6 791 111
Average Daily Capital Traded 1,55%
EPS & Dividend